WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Kevin G. Heiner
Associate
Litigation
Salt Lake City
kheiner@wsgr.com

D801-401-8526

Download vCard
Open PDF

Kevin Heiner is an associate at Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s commercial litigation practice.

Prior to joining the firm, Kevin was an associate at Parr Brown Gee & Loveless, where his practice focused on complex commercial litigation. Previously, Kevin served as a law clerk to Chief Judge Robert J. Shelby of the United States District Court for the District of Utah and to Justice Deno G. Himonas of the Utah Supreme Court.

Experience

Kevin Heiner is an associate at Wilson Sonsini Goodrich & Rosati, where he is a member of the firm’s commercial litigation practice.

Prior to joining the firm, Kevin was an associate at Parr Brown Gee & Loveless, where his practice focused on complex commercial litigation. Previously, Kevin served as a law clerk to Chief Judge Robert J. Shelby of the United States District Court for the District of Utah and to Justice Deno G. Himonas of the Utah Supreme Court.

Education
  • J.D., Columbia Law School, 2018

    James Kent Scholar; Senior Editor, Columbia Law Review

  • B.S., Psychology, University of Utah, 2015
Admissions
  • State Bar of Utah
  • U.S. District Court for the District of Utah
Credentials
Education
  • J.D., Columbia Law School, 2018

    James Kent Scholar; Senior Editor, Columbia Law Review

  • B.S., Psychology, University of Utah, 2015
Admissions
  • State Bar of Utah
  • U.S. District Court for the District of Utah

Select Publications

  • “Are You My Father? Adopting a Federal Standard for Acknowledging or Establishing Paternity in State Court ICWA Proceedings,” 117 Colum. L. Rev. 2151, 2017
Insights

Select Publications

  • “Are You My Father? Adopting a Federal Standard for Acknowledging or Establishing Paternity in State Court ICWA Proceedings,” 117 Colum. L. Rev. 2151, 2017
Focus Areas
  • Commercial Litigation
  • Litigation
Recent Insights
Client Highlights
Wilson Sonsini Secures Total Victory for Inhibrx Biosciences in Trade Secret Misappropriation Trial
On November 1, 2024, a federal jury in Delaware unanimously returned a verdict for Wilson Sonsini clients Inhibrx Biosciences and Dr. Brendan Eckelman. Inhibrx and its co-founder, Dr. Eckelman, are at the forefront of developing innovative therapies to combat cancer using the body’s own immune system. Their novel antibodies aim to both inhibit tumor growth and stimulate immune response.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.